4 insiders bought €2.2M of shares over the last 90 days, the latest filed 17 Aug 2026.
This page follows insider dealings at Chiron Real Estate Inc. as filed with SEC (Form 4), a company from the Real Estate sector. Between 18 October 2025 and 18 October 2026, 7 insiders published 13 filings.
Not one open-market sale was filed. On the buying side, 7 insiders reported 13 purchases totalling €2.8M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 5 senior executives, 1 finance chief and 1 chief executive. One trade stands out by size: a purchase of €858k from Fitzgerald Charles, disclosed on 12 August 2026, or 0.19% of market capitalisation.
In all, 12 purchases were made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The latest purchase dates back some time: it was published 61 days ago, on 17 August 2026. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4.
Compared with its exchange (5,458 companies, median 22 filings), a count of 13 filings is below the norm. Looking back to 2021, when coverage begins, insiders filed 19 purchases and 2 sales.
For comparison within the same sector, see the insider buying recorded at Simon Property Group Inc /DE/ and Angel Oak Mortgage REIT, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
+2 other insiders
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Chiron Real Estate Inc. Buy (bullish), based on 9 analysts. Average price target: US$38.56.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
24 of 24 declarations
Chiron Real Estate Inc. (NYSE: XRN) is a U.S.-listed healthcare real estate investment trust (REIT) focused on investing in the future of healthcare. The company frames its strategy around the intersection of care, capital, and real estate, with a portfolio designed to capture long-term demand driven by aging demographics and the need for healthcare-related property infrastructure. Chiron’s operating base is in Bethesda, Maryland, and the company is organized as a Maryland corporation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1533615/000110465926056346/tm2613785d1_ex99-2.htm))
The most important recent corporate development is the company’s rebranding: Chiron Real Estate Inc. and the XRN ticker became effective on February 23, 2026, signaling a broader strategic repositioning. Management has described this as a reset of mission and values, with an emphasis on delivering value through more targeted healthcare real estate investments and better capital allocation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1533615/000110465926019760/tm267304d1_ex99-2.htm?utm_source=openai))
Operationally, Chiron owns and manages a diversified healthcare property platform. Based on first-quarter 2026 supplemental reporting, the portfolio included about 5.1 million square feet across 189 properties, with annualized cash NOI of roughly $115.3 million and gross assets of about $1.5 billion. The portfolio lease occupancy stood at 95.4% at quarter-end, suggesting a relatively stable rent base. Chiron’s assets span single-tenant outpatient properties, multi-tenant outpatient properties, inpatient rehabilitation facilities, and other healthcare-related real estate. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1533615/000110465926056346/tm2613785d1_ex99-2.htm))
Chiron’s business model combines steady asset-level income with active portfolio management. In 2025, the company completed five acquisitions and seven dispositions, reflecting an ongoing effort to recycle capital and sharpen portfolio quality. It also invested in a Minneapolis-area active adult residential development joint venture, and in May 2026 it announced a strategic preferred equity investment of up to $100 million led by Maewyn Capital Partners. That transaction was presented as a key step in the company’s repositioning toward higher-return opportunities, including senior housing and other targeted healthcare sectors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1533615/000110465926021956/xrn-20251231x10k.htm?utm_source=openai))
From an investment perspective, Chiron appears positioned as a healthcare real estate platform with a defensive income profile but meaningful transformation optionality. The NYSE listing gives it access to U.S. public markets, while the company’s healthcare focus and recent capital-structure actions could support future growth if execution remains disciplined. At the same time, the recent repositioning means investors should watch portfolio reallocation, funding costs, occupancy trends, and the pace at which management converts strategic capital into durable earnings growth. The sources reviewed do not highlight a long operating history or a widely promoted founding date, so the current investment case is best understood through the company’s recent strategic actions rather than through legacy scale alone. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1533615/000110465926056346/tm2613785d1_ex99-2.htm))
Purchases our model currently ranks for the recommendations list.
All recommendations